Diabetic ketoacidosis and mortality in COVID-19 infection

Aim: Patients with diabetes have increased morbidity and mortality from COVID-19. Case reports describe patients with simultaneous COVID-19 and diabetic acidosis (DKA), however there is limited data on the prevalence, predictors and outcomes of DKA in these patients. Methods: Patients with COVID-19 were identified from the electronic medical record. DKA was defined by standardized criteria. Proportional hazard regression models were used to determine risk factors for, and mortality from DKA in COVID-19. Results: Of 2366 patients admitted for COVID-19, 157 (6.6%) patients developed DKA, 94% of whom had antecedent type 2 diabetes, 0.6% had antecedent type 1 diabetes, and 5.7% patients had no prior diagnosis of diabetes. Patients with DKA had increased hospital length of stay and in-patient mortality. Higher HbA1c predicted increased risk of incident DKA (HR 1.47 per 1% increase, 95% CI 1.40-1.54). Risk factors for mortality included older age (HR 1.07 per 5 years, 95% CI 1.06-1.08) and need for pressors (HR 2.33, 95% CI 1.82-2.98). Glucocorticoid use was protective in patients with and without DKA. Conclusion: The combination of DKA and COVID-19 is associated with greater mortality, driven by older age and COVID-19 severity. (c) 2021 Elsevier Masson SAS. All rights reserved.

Automated summary

Patients with diabetes have increased morbidity and mortality from COVID-19. The combination of DKA and COVID-19 is associated with greater mortality, driven by older age and COVID-19 severity. Factors such as higher HbA1c levels, older age, and need for pressors are related to increased risk of mortality in patients with DKA and COVID-19.